Skip to content

Canceled by the investigator. A Feasibility Study of Utilizing the Blood Perfusion Index by Contrast Enhanced Ultrasound to Evaluate the Endovascular Treatment Effect for Lower Limb Arteriosclerosis Obliterans

A Feasibility Study of Utilizing the Blood Perfusion Index by Contrast Enhanced Ultrasound to Evaluate the Endovascular Treatment Effect for Lower Limb Arteriosclerosis Obliterans

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036725
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Limb Arteriosclerosis Obliterans

Interventions

case series:Nil

Sponsors

Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-7 years; 2. Iliac or femoral artery stenosis(no less than 70%) or occlusion and in-stent stenosis, with a patent popliteal artery(no more than 30% stenosis) and at least 1 patent outflow; 3. Fontaine 2-4 or Rutherford 2-4; 4. A patent tibial artery(stenosis:no more than 30%;length:at least 5cm) by doppler ultrasound; 5. Willing to undergo endovascular treatment and without surgical contradictions; 6. Willing to sign the informed consent form; 7. Conform to the clinical study order and willing to complete the 6m follow-up.

Exclusion criteria

Exclusion criteria: 1. Already took part in any other clinical study; 2. Failure of endovascular treatment and conversion to conservative treatment or open surgery; 3. Any of the following conditions: heart failure(NYHA III/IV), heart disease(right to left shunt), severe aortic and mitral insufficiency, acute coronary syndrome, malignant arrhythmia,severe pulmonary hypertension(at least 90mmHg), moderate to severe renal dysfunction(GFR less than 60ml/min),pregant women; 4. Alergy(such as to Sonovue); 5. Life expectancy no more than 1 year.

Design outcomes

Primary

MeasureTime frame
time to peak;peak intensity;area;

Secondary

MeasureTime frame
peak velocity;ancle brachial index;

Countries

China

Contacts

Public ContactWan Zhang

Huadong Hospital

ant0930@163.com+86 18901678909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026